TABLE 1.
Demographic characteristics of SOT recipients diagnosed with COVID‐19, with comparison between those admitted and not admitted
| Characteristics | All (%) | Admitted (%) | Not admitted (%) | P‐value | |||
|---|---|---|---|---|---|---|---|
| Number | 52 (100%) | 40 (77%) | 12 (23%) | ||||
| Median Age (IQR) | 58 (50‐66) | 61 (52‐66) | 50 (36‐53) | .002 | |||
| Male | 34 (65%) | 28 (70%) | 6 (50%) | .202 | |||
| Organ | |||||||
| Kidney | 29 (56%) | 22 (55%) | 7 (58%) | .838 | |||
| Liver | 9 (17%) | 7 (18%) | 2 (17%) | >.99 | |||
| Heart | 6 (12%) | 5 (13%) | 1 (8%) | .655 | |||
| Lung | 6 (12%) | 5 (13%) | 1 (8%) | >.99 | |||
| Multi‐organ | 2 (4%) | 1 (13%) | 1 (8%) | .412 | |||
| Median time from transplant (months) | 43.5 | 45 | 33 | .962 | |||
| Range | 4‐310 | 4‐298 | 5‐310 | ||||
| 0‐3 mo | 0 | 0 | 0 | ||||
| 3‐12 mo | 12 (23%) | 9 (23%) | 3 (25%) | ||||
| Baseline immunosuppression | |||||||
| CNI | 44 (85%) | 34 (85%) | 10 (83%) | ||||
| Mycophenolate/Azathioprine | 38 (73%) | 28 (70%) | 10 (83%) | ||||
| Prednisone | 37 (71%) | 29 (73%) | 8 (67%) | ||||
| Belatacept | 5 (10%) | 3 (8%) | 2 (17%) | ||||
| Sirolimus/Everolimus | 5 (10%) | 4 (10%) | 1 (8%) | ||||
| Rejection in last 3 mo | 1 (2%) | 1 (3%) | 0 (0%) | ||||
| Taking >5 mg prednisone | 4 (8%) | 3 (8%) | 1 (8%) | ||||
| Race/Ethnicity | |||||||
| White | 25 (48%) | 21 (53%) | 4 (33%) | .329 | |||
| Black or African American | 10 (19%) | 9 (23%) | 1 (8%) | .42 | |||
| Hispanic | 17 (33%) | 10 (25%) | 7 (58%) | ||||
| Comorbidities | |||||||
| Hypertension | 43 (83%) | 33 (83%) | 10 (83%) | >.99 | |||
| Diabetes mellitus | 18 (35%) | 15 (38%) | 3 (25%) | .508 | |||
| Chronic renal failure | 39 (75%) | 30 (75%) | 9 (75%) | >.99 | |||
| Chronic lung disease | 9 (17%) | 8 (20%) | 1 (8%) | .666 | |||
| Asthma | 3 (6%) | 3 (8%) | 0 (0%) | >.99 | |||
| HIV | 1 (2%) | 1 (3%) | 0 (0%) | >.99 | |||
| Ischemic heart disease | 12 (23%) | 12 (30%) | 0 (0%) | .047 | |||
| Congestive cardiac failure | 10 (19%) | 9 (23%) | 1 (8%) | .42 | |||
| Hyperlipidemia | 16 (31%) | 14 (35%) | 2 (17%) | .301 | |||
| Active cancer | 1 (2%) | 1 (3%) | 0 (0%) | >.99 | |||
| Current/former smoker | 23 (44%) | 19 (48%) | 4 (33%) | .513 | |||
| BMI (median) (kg/ms) | 27 | 27.1 | 25.1 | .932 | |||
| Admission in Mass General Brigham System | 32 (80%) | ||||||
| Admission OUTSIDE Mass General Brigham | 8 (20%) | ||||||
Abbreviations: BMI, Body mass index; CNI, Calcineurin inhibitor (includes tacrolimus and cyclosporine).